Stock Track | Vericel Plummets 5.24% Intraday on Q1 Loss and Valuation Concerns

Stock Track
May 08

Vericel's stock price dropped 5.24% during intraday trading on Friday, as investors reacted to the company's latest financial results and valuation metrics.

The biotech company reported a Q1 2026 basic EPS loss of US$0.12, which represents a return to loss-making territory after previously profitable quarters. This comes despite the company showing a profitable trailing 12-month period with US$21.5 million in net income.

Investors appear concerned about Vericel's valuation, with the stock trading at a P/E ratio of 83.4x - significantly higher than the US Biotechs industry average of 17.8x. Additionally, the discounted cash flow (DCF) fair value of US$8.53 sits well below the current share price, raising questions about whether the stock's valuation has become stretched.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10